Urogen Pharma Ltd (URGN) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Urogen Pharma Ltd (URGN) following the 2026 Q2 hedge fund 13F filings?

As of today, URGN has moved -10.9% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.9% for the XLV sector ETF — an outperformance of -11.8%. Since the quarter end (June 30, 2026), URGN gained +16.8% vs +6.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Urogen Pharma Ltd (URGN)

186 + Investors. Track Smart Money conviction in URGN. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — URGN

Based on 188 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added URGN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

188 hedge funds hold URGN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +23% more funds vs a year ago

fund count last 6Q

+35 new funds entered over the past year (+23% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 58% buying

107 buying79 selling

Last quarter: 107 funds bought or added vs 79 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

📈

More new buyers each quarter (+14 vs last Q)

new funds entering per quarter

Funds opening a new URGN position: 34 → 31 → 30 → 44. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

46% of holders stayed for 2+ years

■ 46% conviction (2yr+) ■ 28% medium ■ 26% new

86 out of 188 hedge funds have held URGN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Price up while funds trimmed (+90% value, -5% shares)

Value

+90%

-5%

Last quarter: total value of institutional URGN holdings rose +90% even though funds reduced share count by 5%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.

📈

Growing discovery — still being found

41 → 34 → 31 → 30 → 44 new funds/Q

New funds entering each quarter: 34 → 31 → 30 → 44. A growing number of institutions are discovering URGN each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 51% veterans vs 35% newcomers

■ 51% veterans ■ 14% 1-2yr ■ 35% new

Entry-cohort mix of 195 holders: 100 (51%) are 2+ year veterans, 27 entered 1–2 years ago, and 68 (35%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds

43 of 188 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.9

out of 10

Low Exit Risk

Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	186	169	10.06%
13F Shares	43M	47M	-8.57%
Total Value	$1.49B	$810M	84.47%
New Positions	44	30	+14
Increased Positions	58	52	+6
Closed Positions	27	30	-3
Reduced Positions	54	48	+6
Total Calls	4	4	-
Total Puts	3	3	-
PUT/CALL Ratio	0.75	0.75	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

186

169

10.06%

13F Shares

43M

47M

-8.57%

Total Value

$1.49B

$810M

84.47%

New Positions

+14

Increased Positions

Closed Positions

-3

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.75

Neutral

Institutional Holders (2026 Q2)

186 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in URGN. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 URGN holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Acorn Capital Advisors, LLC	16.80%	1,673,420	$61.6M
2	Silverarc Capital Management, LLC	4.98%	1,301,979	$47.9M
3	Kynam Capital Management, LP	4.95%	2,434,207	$89.6M
4	Opaleye Management Inc.	4.80%	1,439,996	$53.0M
5	Superstring Capital Management LP	4.45%	191,313	$7.0M
6	Ally Bridge Group (NY) LLC	2.25%	69,183	$2.5M
7	MPM BioImpact LLC	2.09%	933,415	$34.3M
8	Rtw Investments, LP	1.43%	4,543,895	$167.2M
9	Privium Fund Management B.V.	1.42%	210,000	$7.7M
10	Boxer Capital Management, LLC	1.39%	500,000	$18.4M
11	Elmind Capital, LP	1.11%	120,000	$4.4M
12	Soleus Capital Management, L.P.	1.05%	829,810	$30.5M
13	Aisling Capital Management LP	0.84%	108,000	$4.0M
14	Parkman Healthcare Partners LLC	0.66%	174,064	$6.4M
15	Rice Hall James & Associates, LLC	0.54%	300,650	$11.1M
16	Jefferies Financial Group Inc.	0.53%	2,199,652	$80.9M
17	Frontier Capital Management Co LLC	0.52%	1,508,547	$55.5M
18	Verdad Advisers, LP	0.51%	14,440	$531K
19	Orbimed Advisors LLC	0.46%	676,187	$24.9M
20	ADAR1 Capital Management, LLC	0.43%	252,395	$9.3M
21	Hennion & Walsh Asset Management, Inc.	0.29%	276,696	$10.2M
22	Birchview Capital, LP	0.28%	16,487	$607K
23	Informed Momentum Co LLC	0.26%	79,271	$2.9M
24	HighVista Strategies LLC	0.21%	24,968	$919K
25	J. Goldman & Co LP	0.20%	212,775	$7.8M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Urogen Pharma Ltd (URGN)

What does the Smart Money Trend signal show for URGN?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added URGN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for URGN?

Slight buying edge — 58% buying: Last quarter: 107 funds bought or added vs 79 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for URGN holders?

Strong quality — 36% AUM from major funds: 43 of 188 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held URGN?

46% of holders stayed for 2+ years: 86 out of 188 hedge funds have held URGN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Urogen Pharma Ltd (URGN) following the 2026 Q2 hedge fund 13F filings?

As of today, URGN has moved -10.9% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.9% for the XLV sector ETF — an outperformance of -11.8%. Since the quarter end (June 30, 2026), URGN has gained +16.8% vs +6.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Urogen Pharma Ltd (URGN)

Smart Money Signals — URGN

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Fast accumulation — +23% more funds vs a year ago

Slight buying edge — 58% buying

More new buyers each quarter (+14 vs last Q)

46% of holders stayed for 2+ years

Price up while funds trimmed (+90% value, -5% shares)

Growing discovery — still being found

Veteran-anchored — 51% veterans vs 35% newcomers

Strong quality — 36% AUM from major funds

Institutional Sentiment Summary — URGN

Hedge Fund Ownership: URGN

Market Analysis: URGN

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: URGN

Is It Too Late to Buy Urogen Pharma Ltd (URGN) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: URGN

Statistics: URGN

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Urogen Pharma Ltd (URGN)

Welcome to 13Foresight!